SCHEMBL26158656

SCHEMBL26158656

CCc1cc(OCc2ccccc2)cc(C(=O)O)c1OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
LTB4R Q15722 2/20 0.49
LTB4R2 Q9NPC1 2/20 0.49
CTSV O60911 2/20 0.49
CTSL P07711 2/20 0.49
MAOB P27338 3/20 0.49
MCL1 Q07820 2/20 0.49
NR4A2 P43354 2/20 0.49
NR4A1 P22736 1/20 0.49
NR4A3 Q92570 1/20 0.49
SLC16A3 O15427 1/20 0.48
SRD5A2 P31213 3/20 0.46
HPGD P15428 2/20 0.46
LMNA P02545 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23803634 0.89 MEN1 (0.55) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL23796860 0.88 MEN1 (0.65) MEN1KMT2ACTSVCTSLMAOB
SCHEMBL30031228 0.86 MEN1 (0.52) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL23803621 0.86 MEN1 (0.52) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL23817091 0.86 MEN1 (0.52) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL10657327 0.86 MEN1 (0.55) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL28067837 0.86 DHODH (0.48) MEN1KMT2ALTB4RLTB4R2MCL1
SCHEMBL23817241 0.83 MEN1 (0.47) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL23817100 0.82 MEN1 (0.46) MEN1KMT2ALTB4RLTB4R2CTSV
SCHEMBL2955611 0.82 LTB4R (0.64) MEN1KMT2ALTB4RLTB4R2CTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150951-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS OM PHARMA SA (CH) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150951-A1 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS HRH4, NCOA4, HRH3 MEN1 815/4885KMT2A 3173/4885LTB4R 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.